With the launch of COBENFY, a first-in-class schizophrenia treatment, Bristol Myers Squibb needed a brand experience that could do more than educate. It needed to inspire belief. As the first new class of treatment in more than 30 years, COBENFY offered real progress in a space that had long felt stagnant. But to connect with patients, caregivers, and providers, the brand had to do more than show up. It had to awaken a new kind of presence from the very first impression.